AptaBio Therapeutics Inc. (KOSDAQ:293780)
South Korea
· Delayed Price · Currency is KRW 8,370.00
+70.00 (0.84%)
Apr 29, 2026, 1:09 PM KST
AptaBio Therapeutics Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Operating Revenue | 3,698 | 3,361 | 323.87 | 48.35 |
| Other Revenue | -0 | - | - | - |
| Revenue | 3,698 | 3,361 | 323.87 | 48.35 |
| Revenue Growth (YoY) | 10.03% | 937.76% | 569.80% | - |
| Cost of Revenue | 2,409 | 3,087 | 262.8 | 11.15 |
| Gross Profit | 1,289 | 273.69 | 61.06 | 37.21 |
| Selling, General & Admin | 5,569 | 3,893 | 3,385 | 2,788 |
| Research & Development | 10,501 | 14,591 | 12,380 | 6,197 |
| Amortization of Goodwill & Intangibles | 11.79 | 21.73 | 23.34 | 14.53 |
| Other Operating Expenses | 199.64 | 113.05 | 130.03 | 74.48 |
| Operating Expenses | 16,825 | 20,989 | 16,965 | 9,544 |
| Operating Income | -15,536 | -20,715 | -16,904 | -9,507 |
| Interest Expense | -2,118 | -3,401 | -1,183 | -4.49 |
| Interest & Investment Income | 1,265 | 2,296 | 1,984 | 1,572 |
| Earnings From Equity Investments | -2,653 | -625.93 | -4.19 | - |
| Currency Exchange Gain (Loss) | 40.15 | -252.8 | -29.52 | -14.43 |
| Other Non Operating Income (Expenses) | 3,812 | -4,651 | 1,688 | 42.49 |
| EBT Excluding Unusual Items | -15,190 | -27,350 | -14,448 | -7,911 |
| Impairment of Goodwill | -475.11 | - | - | - |
| Gain (Loss) on Sale of Investments | 324.71 | -452.59 | -244.29 | -2,654 |
| Pretax Income | -15,340 | -27,803 | -14,692 | -10,565 |
| Income Tax Expense | 1,006 | 1,575 | -2,630 | - |
| Net Income | -16,346 | -29,378 | -12,062 | -10,565 |
| Preferred Dividends & Other Adjustments | - | - | -195.14 | - |
| Net Income to Common | -16,346 | -29,378 | -11,866 | -10,565 |
| Shares Outstanding (Basic) | 27 | 24 | 22 | 22 |
| Shares Outstanding (Diluted) | 27 | 24 | 22 | 22 |
| Shares Change (YoY) | 14.40% | 5.57% | 0.05% | - |
| EPS (Basic) | -607.00 | -1248.00 | -532.16 | -474.00 |
| EPS (Diluted) | -607.00 | -1248.00 | -532.16 | -474.00 |
| Free Cash Flow | -15,335 | -12,400 | -15,440 | -7,874 |
| Free Cash Flow Per Share | -569.45 | -526.76 | -692.42 | -353.27 |
| Gross Margin | 34.84% | 8.14% | 18.86% | 76.95% |
| Operating Margin | -420.14% | -616.35% | -5219.25% | -19661.23% |
| Profit Margin | -442.04% | -874.09% | -3663.98% | -21849.26% |
| Free Cash Flow Margin | -414.69% | -368.94% | -4767.39% | -16284.04% |
| EBITDA | -15,056 | -20,184 | -16,364 | -9,022 |
| D&A For EBITDA | 480.81 | 531.35 | 539.11 | 484.62 |
| EBIT | -15,536 | -20,715 | -16,904 | -9,507 |
| Advertising Expenses | 647.07 | 9 | 3 | 7.07 |
Source: S&P Capital IQ. Standard template. Financial Sources.